Drug Interchangeability: Biosimilar Products

Authored by: Laszlo Endrenyi , Shein-Chung Chow , Laszlo Tothfalusi

Encyclopedia of Biopharmaceutical Statistics

Print publication date:  August  2018
Online publication date:  August  2018

Print ISBN: 9781498733953
eBook ISBN: 9781351110273
Adobe ISBN:

10.1201/9781351110273-140000047

 Download Chapter

 

Abstract

When the patent of a biological drug expires, alternative, biosimilar products are often developed. They are expected to have highly similar clinical effects with the original drug. Still, even after the approval of the biosimilarity of two drug products, their interchangeability within subjects remains to be determined. Regulatory authorities in the United States, Canada and the European Union follow differing approaches to the approval of interchangeability. The disbursement of funds for drugs and, consequently, the decisions for interchangeability are generally left for the states, provinces and constituent states. This leads to widely diverging practices and, in the United States, possible legal complications. Statistical approaches are presented for the determination of the switching, alternation and interchangeability of biological products and for the design of the corresponding studies.

 Cite
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.